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Multiple sclerosis (MS) is an infl  ammatory   disease 
of the central nervous system (CNS) character-
ized by recurrent episodes of immune-mediated 
attack on oligodendrocytes leading to myelin and 
axon damage and progressive motor and cogni-
tive disability (1, 2). Examination of the gene 
  expression profi  les of MS plaques has revealed 
abundant evidence of Th1-, Th17-, and B cell–
mediated immunological activity (3). Studies 
in experimental autoimmune encephalomyelitis 
(EAE) and in MS suggest that Th1 eff  ector cells 
are important in initiating acute attacks (4, 5). 
Myelin-reactive Th1 cells comprise the majority 
of CNS-infi  ltrating cells during acute EAE (4), 
and treatment with IFN-γ causes relapses in MS 
(6). On the other hand, Th17 cells, although 
highly encephalitogenic (4), appear to be less 
  relevant to acute EAE but important in mediat-
ing progression of this disease (5). Consistent 
with this, IL-17 is expressed at higher levels in 
chronic versus acute MS lesions (3). In contrast, 
Th2 cytokines such as IL-4 are associated with 
amelioration of EAE and remission in MS (7, 8).
An interesting feature of MS is that twice as 
many women as men develop the disease (9). 
Women are also more susceptible than men to 
develop a host of other autoimmune   conditions, 
including rheumatoid arthritis (female to male 
ratio of 2:1), systemic lupus erythematosus 
(9:1), Sjogren’s syndrome (9:1), and Hashimoto’s 
thyroiditis (9:1) (9). The higher female preva-
lence of these diseases may be related to the fact 
that women develop more robust immune 
  responses than men (10). Women have higher 
plasma levels of IgM (11) and higher CD4+ cell 
counts (12), and show stronger humoral- and 
cell-mediated responses to vaccination with a 
variety of antigens (10). Women are also reported 
to be more prone than male counterparts to de  -
velop Th1-polarized responses directed ag  ainst 
myelin antigens during MS (13).   Studies in 
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mice have shown that this propensity to develop Th1 immu-
nity also helps females clear certain viruses (i.e., Theilers mu-
rine encephalomyelitis and herpes simplex virus-1) more 
eff  ectively (14–16). Whether gender diff  erences also exist in 
the development of Th17 immunity is not known.
Although the molecular basis of the gender dichotomy in 
the development of Th1↔Th2 immunity is not understood, 
a large body of evidence suggests that sex hormones, particu-
larly androgens, infl  uence this process (10, 17). For instance, 
the castration of male mice, but not the ovariectomy of female 
mice, enhances Th1 autoimmunity and lowers Th2 cytokine 
production, leading to exacerbation of EAE (17–18) and ac-
celeration of lupus (19) and diabetes (20) in animal models. 
In contrast, exogenous administration of testosterone or 
α-dihydroxytestosterone (DHT) promotes a Th2 bias in cyto-
kine production that leads to suppression of these Th1-mediated 
autoimmune diseases (18, 21, 22). Akin to this, male MS and 
rheumatoid arthritis patients are reported to have diminished 
testosterone levels compared with age-matched controls 
(23, 24), and androgen treatment relieves clinical symptoms in 
hypogonadal patients with rheumatoid arthritis (25). Recent 
studies suggest that androgens act directly on CD4+ cells to 
increase Th2 cytokine production (22, 26). However, the 
genes in T cells that are sensitive to androgens and modulate 
Th responses have not been identifi  ed.
One potential gene candidate is peroxisome proliferator–
activated receptor (PPAR)α, a member of the nuclear hor-
mone receptor subfamily. This transcription factor, along 
with other PPAR family members, regulates whole body 
lipid and glucose homeostasis and controls infl  ammatory re-
sponses (27, 28). In metabolic tissues such as the liver, ligand 
activation of PPARα via either natural fatty acid intermedi-
ates (i.e., unsaturated fatty acids and leukotreine B4) or syn-
thetic fi  brate drugs (i.e., Gemfi  brozil) leads to transcriptional 
activation of a subset of mitochondrial and peroxisomal en-
zymes that are involved in lipid mobilization and catabolism 
(28). However, in immune cells, PPARα primarily functions 
to inhibit infl  ammatory pathways through sequestration and 
repression of c-jun and NF-κB transcription factors (27, 29). 
Interestingly, studies of the hepatic function of PPARα have 
shown that this nuclear receptor is expressed at a higher level 
in male as compared with female rats (30) and can mediate 
gender dimorphism in lipid metabolism (31–33).
Here, we report that gender diff  erences in PPARα action 
also extend to the antiinfl  ammatory activities of this receptor. 
We show that PPARα is expressed at higher levels in male as 
compared with female T cells in mice and that this expression 
is reduced by castration and increased by α-DHT treatment. 
We also show that defi  ciency of the PPARα gene selectively 
aff  ected the functioning of male T lymphocytes such that it 
resulted in higher IFN-γ and TNF (but not IL-17) production 
by these cells. Moreover, in comparison to WT counterparts, 
male but not female PPARα−/− mice developed more severe 
EAE that was restricted to the acute phase of disease. These 
fi  ndings thus provide a molecular basis for why males may be 
less prone to developing Th1-mediated autoimmunity.
RESULTS
PPAR𝗂−/− mice develop more severe EAE, but only in males
It has been reported that PPARα has a more prominent role 
in regulating lipid metabolism in male rodents (30–33). To 
investigate whether the gender dimorphism in PPARα 
  function also extends to antiinfl  ammatory activities of this re-
ceptor, we compared the clinical course of EAE in male and 
female WT versus PPARα−/− mice. EAE was induced in 
these mice (SV.129 strain, H2b) via immunization with a 
  peptide encoding amino acids 35–55 of myelin oligodendro-
cyte glycoprotein (MOG p35-55) in CFA. We found in two 
separate experiments that male PPARα−/− mice displayed a 
more severe clinical course of EAE compared with WT 
counterparts, particularly in the acute phase of disease (Fig. 1, 
A and B, and Table I). Although disease appeared more 
chronic in male PPARα−/− mice in Fig. 1 A, it is because 
half of the mice died in the acute phase and were given a 
clinical score of 5 for the remaining days of the experiment. 
In contrast to fi   ndings for males, the severity of EAE in 
Figure 1.  Male PPAR𝗂−/− mice developed more severe clinical 
signs and displayed increased numbers of infl  ammatory brain lesions 
in the acute phase of EAE. Male and female WT or PPARα−/− SV.129 
mice (n = 8–10/group) were immunized with MOG p35-55 in CFA and 
given intravenous injections of pertussis toxin on days 0 and 2 after 
  immunization. (A and B) Mean + SEM clinical scores of mice in the dif-
ferent groups at various times after immunization. Shown are results of 
two independent EAE experiments. * indicates a signifi  cant difference 
from WT group (P < 0.05) as determined using a Mann-Whitney U 
  statistic. (C) Paraffi  n-embedded sections of brain stem and cerebellum 
from representative male WT and PPARα−/− mice (from experiment no. 2) 
during the acute phase of EAE stained with hematoxylin and eosin. Bar in 
the bottom right, 50 μM.JEM VOL. 204, February 19, 2007  323
ARTICLE
PPARα−/− females was almost indistinguishable from WT 
counterparts (Fig. 1, A and B, and Table I). Analysis of the 
histological features of EAE in male mice revealed that com-
pared with WT, PPARα−/− mice showed higher numbers of 
parenchymal infl  ammatory foci in the cerebellum and brain-
stem in the acute phase of EAE (Fig. 1 C and Table I).
There appeared to be an immune basis for the more 
  severe clinical phenotype in male PPARα−/− mice because 
MOG p35-55–reactive splenocytes from these mice prolifer-
ated more robustly (Fig. 2 A, left) and secreted higher levels 
of Th1 cytokines, such as IFN-γ and TNF, and lower levels 
of the antiinfl  ammatory cytokine IL-10 (Fig. 2 B, left) com-
pared with male WT splenocytes. Interestingly, the absence 
of PPARα in male splenocytes also resulted in lower produc-
tion of IL-17 (Fig. 2 A, left). On the other hand, although 
female PPARα−/− MOG p35-55–reactive splenocytes dis-
played heightened proliferative responses (Fig. 2 A, right), no 
major diff  erences in cytokine production were apparent be-
tween female WT and PPARα−/− groups (Fig. 2 B, right).
Analysis of splenic leukocyte distributions revealed a ten-
dency (P = 0.1) for a higher T cell/B cell ratio in PPARα−/− 
mice of both genders (Table II), which may explain the 
higher proliferation, but not the sex diff  erences in cytokine 
production of MOG p35-55–reactive PPARα−/− splenocytes. 
Collectively, these results suggest that PPARα selectively 
  operates in male mice to suppress the development of 
Th1-mediated autoimmunity.
T cells from male but not female PPAR𝗂−/− mice 
are hyperresponsive to TCR stimulation and trigger 
an earlier onset of EAE
PPARα is expressed in T and B lymphocytes (27) and is 
  detected at low levels in peritoneal macrophages and immature 
dendritic cells (34). To examine whether the enhanced 
Th1-mediated autoimmunity in male PPARα−/− mice was a 
Figure 2.  Splenocytes from MOG-immunized male PPAR𝗂−/− mice 
secreted higher levels of IFN-𝗄 and TNF compared with WT coun-
terparts. Splenocytes from male and female SV.129 WT or PPARα−/− 
mice were harvested 10 d after EAE induction and stimulated with 0–20 
μg/ml MOG p35-55. (A) Proliferation of cells in response to 5 μg/ml MOG 
peptide was measured by [3H]thymidine incorporation (cpm). Values are 
means ± SEM counts of radioactivity per minute (cpm) of triplicate cul-
ture wells. (B) Cytokine levels in culture supernatants were measured by 
ELISA at 48 (IL-17), 72 (IFN-γ and TNF), and 120 h (IL-10) after stimula-
tion. Values are means ± SEM of cytokine levels (pg/ml) in triplicate cul-
ture wells. Note that IL-4 was not detected in culture supernatants. 
Results are representative of two to three independent experiments.
Table I.  Clinical and histological features of EAE in male and 
female WT and PPARα−/− mice
WT
male
PPARα−/−
male
WT
female
PPARα−/−
female
Clinical features
Maximum score
  Experiment 1 2.5 (0.3) 3.8 (0.4)a 1.9 (0.2) 1.9 (0.2)
  Experiment 2 2.4 (0.5) 3.5 (0.3)a 2.7 (0.6) 2.9 (0.3)
Death from disease
 Experiment  1 0/8 3/7 0/18 0/15
 Experiment  2 1/8 1/8 2/9 1/9
Incidence
 Experiment  1 8/8 7/7 17/18 14/15
 Experiment  2 8/8 8/8 7/9 9/9
Day of onset
 Experiment  1 14.2 (1.2) 12.8 (0.3) 13.9 (0.8) 14.5 (1.0)
 Experiment  2 16.4 (1.7) 12.2 (0.2)a 14.4 (1.8) 11.1 (0.5)
Cumulative scoreb
 Experiment  1 12.5 (2.3) 25.3 (5.2)a 9.2 (1.4) 10.3 (1.6)
 Experiment  2 16.6 (6.2) 23.3 (9.5) 19.4 (7.0) 22.8 (6.1)
Histological features (Experiment 2)
Parenchymal infl  ammatory foci
  Cerebellum 15 (8) 31 (13) 12 (2) 12 (7)
  Brain stem 10 (4) 23 (1)a 22 (11) 8 (4)
  Cerebrum 16 (6) 39 (14) 14 (4) 2 (1)a
  Spinal cord 23 (15) 49 (6) 23 (9) 32 (18)
  Total 64 (33) 142 (27) 71 (21) 54 (31)
Meningeal infl  ammatory foci
139 (55) 147 (7) 123 (11) 58 (12)a
Values are means (SEM).
aA signifi  cant difference from WT counterpart; P < 0.05.
bUp until day 22 (approximate time of remission after acute phase).324  PPARα MEDIATES GENDER DIFFERENCES IN AUTOIMMUNITY | Dunn et al.
result of intrinsic diff  erences in these immune populations, 
we purifi  ed CD3+ T cells, B cells, and macrophages from 
male and female WT and PPARα−/− mice and compared 
the   activation responses of these cells ex vivo. Consistent 
with previous reports (26), we found that female WT CD3+ 
cells proliferated more robustly and secreted higher levels of 
IFN-γ and TNF and lower amounts of Th2 cytokines (IL-4 
and IL-10) as compared with male WT CD3+ cells in re-
sponse to anti-CD3 and anti-CD28 costimulation (Fig. 3 A). 
Female CD3+ cells also produced higher levels of IL-17. On 
the other hand, male and female PPARα−/− T cells displayed 
similar activation characteristics that more closely resembled 
the Th1 profi  le of female WT cells (Fig. 3 A), with the ex-
ception that IL-17 production remained low in PPARα−/− 
male cells. Similar results were observed using CD4+-  purifi  ed 
cells (not depicted). Notably, we did not observe major sex 
diff  erences in the LPS- or IgM-elicited responses of purifi  ed 
B cells or LPS- or IFN-γ–elicited responses of peritoneal 
macrophages derived from WT or PPARα−/− mice (not 
  depicted), thus indicating that intrinsic diff  erences in T cells 
are likely responsible for the enhanced Th1 autoimmunity 
observed in male PPARα−/− mice.
To test this notion, we reconstituted male and female 
RAG2−/− mice with gender-matched syngeneic PPARα−/− 
CD4+ T cells to generate chimeric mice that were PPARα 
suffi   cient except for their CD4+ T cell population. Upon in-
duction of EAE, mice transferred with male PPARα−/− T cells 
showed a much earlier onset of clinical signs compared with 
male RAG2−/− mice reconstituted with male WT T cells (Fig. 
3 B). In contrast, diff  erences in disease onset were not apparent 
between these two groups in females (Fig. 3 B), confi  rming 
that intrinsic diff  erences in T cells likely contribute to the more 
severe acute EAE developed in male PPARα−/− mice.
PPAR𝗂 is more abundant in male as compared with female 
T cells and represses the DNA binding of NF-𝗋B and c-jun
In light of reports of gender diff  erences in hepatic PPARα 
expression (30), we investigated whether the selective infl  uence 
of PPARα on the functioning of male T cells is due to higher 
levels of expression of this nuclear receptor. Consistent with 
this notion, we found that PPARα mRNA expression was 
higher in male as compared with female CD4+ cells derived 
from SV.129 (Fig. 4 A), C57/B6, or SJL/J mice (Fig. S1, A 
and B, available at http://www.jem.org/cgi/content/full/
jem.20061839/DC1). This trend for higher male   expression 
was also evident at the protein level as detected via Western 
blot analysis of nuclear extracts from naive T cells (Fig. 4 B). 
Compared with the situation in naive T cells, gender diff  er-
ences in PPARα mRNA expression were not as striking 
in CD4+ cells at 48 h after stimulation with anti-CD3 and 
anti-CD28 (Fig. S1 C). The latter fi  nding suggests that 
PPARα may mediate the gender dichotomy in Th1↔Th2 
diff  erentiation by infl  uencing T cell responses in the early 
period after antigen encounter.
Figure 3.  T cells from male PPAR𝗂−/− mice were hyperresponsive 
to TCR stimulation and caused an earlier onset of EAE. (A) CD3+ 
T cells from male and female SV.129 WT or PPARα−/− mice were stimu-
lated with 1 μg/ml anti-CD3 and anti-CD28. The proliferation rate was 
determined by [3H]thymidine incorporation (cpms), and cytokine produc-
tion was measured in culture supernatants by ELISA at 48 (IL-2), 72 
(IFN-γ, TNF, and IL-17), and 120 h (IL-10 and IL-4) after stimulation. Val-
ues are means ± SEM of triplicate culture wells. * indicates a signifi  cant 
difference (P < 0.05) from WT counterpart. Results are representative of 
at least three independent experiments. (B) Naive CD4+ T cells from male 
and female WT and PPARα−/− mice were adoptively transferred into 
syngeneic male or female RAG2−/− mice by intravenous injection, and 
EAE was induced in recipient mice 2 d later via immunization with MOG 
p35-55 in CFA. Mean clinical scores of mice in the different groups at 
various times after immunization are shown. Results are representative 
of two independent experiments. * indicates a signifi  cant difference from 
WT (P < 0.05).
Table II.  Cellular composition of the spleen of male and 
female WT and PPARα−/− SV.129 mice
Cell marker WT male PPARα−/− male WT female PPARα−/− female
CD3+ 30.9 (1.9) 35.2 (5.1) 31.7 (2.0) 36.1 (3.1)
CD8+ 8.7 (0.5) 9.1 (1.9) 9.9 (0.4) 11.3 (1.4)
CD4+ 18.4 (0.8) 20.2 (2.2) 20.7 (0.8) 22.7 (1.1)
CD4+CD25+ 4.2 (2.2) 3.5 (1.6) 5.4 (1.4) 4.7 (1.0)
CD11b+ 3.6 (0.1) 3.8 (0.8) 5.4 (0.5) 4.0 (1.4)
CD11c+ 2.1 (0.5) 1.5 (0.2) 1.9 (0.3) 2.0 (0.5)
B220+ 65.5 (1.1) 57.5 (6.3) 55.8 (5.3) 50.7 (4.0)
CD3+/B220 0.47 0.61 0.56 0.72
Values are means (SEM) of three experiments. There were no signifi  cant differences 
between groups.JEM VOL. 204, February 19, 2007  325
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It has been reported that upon ligand activation, PPARα 
binds to and represses NF-κB or c-jun, preventing these 
transcription factors from binding DNA (29). Both NF-κB 
and c-jun convey signals downstream of the TCR, IL-18R, 
and CD28 to transactivate the IFN-γ promoter and promote 
Th1 diff  erentiation (35–37). Consistent with our fi  nding of 
higher male expression of PPARα, we found that the DNA 
binding of NF-κB or c-jun to target DNA consensus  elements 
was lower in male as compared with female WT T cells, and 
that it was selectively increased in male T cells in the absence 
of PPARα (Fig. 4 C). This higher NF-κB and c-jun activity 
in male PPARα−/− T cells was also associated with a lower 
threshold of activation of these cells such that they produced 
IFN-γ at much lower concentrations of anti-CD3 and   anti-
CD28 as compared with male WT counterparts (Fig. 4 D). 
In contrast to fi  ndings of male T cells, NF-κB activity was 
lower in female PPARα−/− as compared with female WT 
cells (Fig. 4, C and D).
In addition to PPARα, T cells also express lower levels of 
PPARγ and PPARδ, which can also transrepress NF-κB 
  activity (27). We therefore investigated whether the gender 
dimorphism in T cell activation was related to expression of 
these other PPAR isoforms. Real-time RT-PCR analysis 
showed that PPARγ had an opposite pattern of expression 
than PPARα, with relatively higher mRNA levels in female 
as compared with male CD4+ T cells, whereas sex diff  erences 
in PPARδ mRNA expression were not apparent in these 
cells (Fig. S1 D). Interestingly, the mRNA levels of PPARγ 
and PPARδ were both elevated in a compensatory fashion in 
PPARα−/− cells. This fi  nding that male PPARα−/− cells 
were hyperresponsive and displayed higher NF-κB activity 
in the face of elevations in PPARγ and PPARδ highlights 
the special regulatory role of PPARα in male T cells. On the 
other hand, the higher expression of PPARγ and PPARδ in 
female PPARα−/− T cells (Fig. S1 D) did appear to have a 
functional impact because it was associated with lowered 
NF-κB activity in these cells (Fig. 4 C).
PPAR𝗂 expression is sensitive to testosterone and mediates 
androgen sensitivity of Th responses
Given the male bias in PPARα expression in T cells, we next 
investigated whether this gene is sensitive to androgen levels. 
We found that castration of male mice, which lowered serum 
testosterone (0.05 ± 0.01 ng/dL in castrated vs. 6.21 ± 2.91 
ng/dL in sham-operated mice), decreased the mRNA levels 
of PPARα in CD4+ T cells pooled from these mice (Fig. 5 A). 
On the other hand, implantation of female mice with pellets 
containing the testosterone metabolite 5α-DHT (5 mg) 
greatly enhanced the expression of PPARα in CD4+ T cells 
over levels observed in the placebo-treated group (Fig. 5 B). 
We also investigated the association between PPARα in 
T cells and serum testosterone levels in individual male mice 
(n = 10 mice in two cages). As is typical of group-housed 
males, several males in the cohort had serum testosterone lev-
els that were  10-fold higher than cage mates (Fig. 5 C). In-
terestingly, these dominant males, as defi  ned by testosterone 
levels, also displayed the highest transcript levels of PPARα 
in their T cells (Fig. 5 C). Collectively, these fi  ndings suggest 
that the   expression of PPARα in T cells correlates with 
  circulating androgen levels.
It is reported that reduction in androgen levels with 
  castration enhances the development of Th1 responses and 
suppresses the development of Th2 responses in male mice 
(22). To determine the extent to which changes in 
PPARα expression contribute to the androgen sensitivity 
of Th responses, we contrasted the eff  ects of castration on 
the cytokine production of male WT versus PPARα−/− 
T cells. Consistent with previous fi  ndings, castration   enhanced 
production of Th1 cytokines (IFN-γ, IL-2, and TNF) and 
Figure 4.  PPAR𝗂 was more abundant in male as compared with 
female T cells and was associated with decreased NF-𝗋B and c-jun 
activity and increased IFN-𝗄 production. (A) Total RNA was obtained 
from naive CD4+ T cells that were pooled from the spleens of male and 
female SV.129 mice (n = 4 mice/group). The expression of PPARα mRNA 
in these cells was measured using real-time RT-PCR, and abundance was 
expressed relative to β-actin mRNA. Values are means ± SEM of PPARα/
β-actin product abundance in triplicate reactions expressed in arbitrary 
units (AU). (B) Western blot analysis of PPARα in nuclear extracts (250 μg) 
prepared from male and female T cells. Histone H3 was used as a 
loading control. (C) c-jun (left) and NF-κB (right) DNA binding was mea-
sured in nuclear extracts from male and female SV.129 WT or PPARα−/− 
CD3+ T cells using an ELISA-based assay. Nuclear extracts were prepared 
from T cells at 16 h after stimulation with 5 μg/ml anti-CD3 and 5 μg/ml 
anti-CD28. Values are means ± SEM of absorbance units (duplicate 
  culture wells) of stimulated wells expressed relative to absorbance in 
  nonstimulated control wells. (D) CD3+ T cells from male and female 
SV.129 WT or PPARα−/− mice were stimulated with 0–2 μg/ml anti-CD3 
(left) and 0–5 μg/ml anti-CD28 (right). IFN-γ production in culture 
  supernatants was measured by ELISA at 72 h after stimulation. Values are 
means ± SEM of triplicate culture wells. Note that anti-CD28 and anti-
CD3 were held constant at 0.5 μg/ml in the left and right panels, respec-
tively. Results in A–D are representative of two independent experiments.326  PPARα MEDIATES GENDER DIFFERENCES IN AUTOIMMUNITY | Dunn et al.
reduced the production of the Th2 cytokine IL-4 by WT 
T cells cultured ex vivo with anti-CD3 and anti-CD28 
(Fig. 5 D). Castration also enhanced the production of 
IL-17 and IL-10 by T cells (Fig. 5 D). Interestingly, this eff  ect 
of castration on cytokine production was blunted in 
T cells derived from PPARα−/− mice (Fig. 5 D), confi  rming 
that changes in PPARα expression mediate a major part of 
the eff  ects of androgens on T cell cytokine responses.
Treatment of mice with the PPAR𝗂 agonist Gemfi  brozil 
reduces the incidence of EAE only in male mice
Previously, it was reported that oral administration of 25 
mg/kg Gemfi  brozil, a potent agonist of PPARα, ameliorates 
EAE in female B10.PL mice in part by inducing a Th2 bias 
of myelin-reactive T cells (38). To investigate whether males, 
in having higher expression of PPARα in naive T cells, are 
more responsive to the eff  ects of fi  brates, we induced EAE in 
male and female C57BL/6 mice and administered either 
Gemfi  brozil (25 or 50 mg/kg) or vehicle once daily via 
  gavage. 25 and 50 mg/kg treatment groups were not diff  erent 
(P > 0.05) and were pooled for analysis. Although Gem-
fi  brozil treatment tended to decrease the maximum clinical 
scores of both male (1.3 ± 0.5 in Gemfi  brozil vs. 2.4 ± 0.7 
in vehicle) and female mice (2.4 ± 0.4 in Gemfi  brozil vs. 3.3 ± 
0.6 in vehicle) as compared with the vehicle control group, it 
lowered the incidence of disease only in males (43% in Gem-
fi  brozil vs. 71% in vehicle group in males; 79% in Gemfi  bro-
zil vs. 82% in vehicle group in females). These results provide 
further support for a role for PPARα in modulating 
the threshold of activation during the initial priming of 
auto  reactive T cells.
DISCUSSION
Compared with males, females mount heightened Th1 
  immunity in response to immunization with a variety of 
  antigens. This propensity to develop Th1 immune responses 
also correlates with the greater likelihood of females to de-
velop MS and other autoimmune diseases (9). Studies in EAE 
have demonstrated that gender diff  erences in immunity are 
shaped by the levels of androgens that are present in the lym-
phoid microenvironment during the initial development of 
the encephalitogenic T cell responses (22, 26). In the present 
study, we identify PPARα as a gene in CD4+ T cells that is 
sensitive to androgen levels and through expression changes 
can infl  uence the development of Th fate. We show that 
PPARα is expressed at higher levels in male as compared 
with female naive T cells, which correlates with lowered 
TCR-induced NF-κB and c-jun activity and higher Th2 cy-
tokine production by these cells. Genetic ablation of PPARα 
selectively removed the brake on NF-κB and c-jun in male 
T lymphocytes, resulting in an increased production of IFN-
γ and TNF, but not IL-17. These hyper-Th1 male PPARα−/− 
CD4+ cells caused more severe paralysis during EAE that was 
restricted to the acute phase of disease.
Our fi  nding that the sex diff  erences in PPARα expres-
sion were more prominent in naive than in activated T cells 
suggests that this nuclear receptor may mediate gender di-
morphism in encephalitogenic T cell responses in the early 
period after antigen priming. This window of T cell activa-
tion is a time when Th fate is infl  uenced by the strength of 
signaling downstream of the TCR and CD28 (39, 40). For 
instance, antigens that bind the TCR weakly induce transient 
activation of downstream pathways (i.e., MAPK) that favors 
Th2 diff  erentiation, whereas antigens that bind to the TCR 
with strong avidity trigger more sustained MAPK signaling 
events that lead to Th1 diff  erentiation (39, 40). Taken in this 
light, our fi  nding that elevated PPARα expression in male 
T cells was associated with decreased DNA binding of 
  transcription factors (NF-κB and c-jun) that transactivate the 
IFN-γ promoter downstream of the TCR-MAPK and CD28 
signaling (35, 37) explains why male naive T cells may be less 
likely to diff  erentiate along the Th1 path. The fi  ndings that 
PPARα did not infl  uence TCR- and CD28-induced IL-17 
Figure 5.  PPAR𝗂 mediates androgen sensitivity of Th responses. 
(A and B) Total RNA was obtained from naive CD4+ T cells that were 
pooled from the spleens of castrated- or sham-operated male (n = 4 
mice/group) (A) or placebo or α-DHT pellet-implanted female (n = 4 
mice/group) (B) mice. The expression of PPARα mRNA in these cells was 
measured using real-time RT-PCR, and abundance was expressed relative 
to β-actin mRNA. Values are means ± SEM of PCR product abundance in 
arbitrary units (AU). * indicates a signifi  cant difference (P < 0.05) from 
either sham (A) or placebo (B). (C) Correlation of serum testosterone 
(ng/dL) and T cell PPARα mRNA levels in 10 individual mice that were group 
housed in two cages. (D) CD3+ T cells from sham or castrated male WT 
and PPARα−/− mice were isolated at 4 wk after surgery and stimulated 
with 1 μg/ml anti-CD3 and 0.5 μg/ml anti-CD28. Cytokine secretion by 
T cells was assessed by ELISA analysis of culture supernatants at 48 (IL-2), 
72 (IFN-γ, TNF, and IL-17), and 120 h (IL-10) after stimulation. Values are 
means ± SEM of cytokine levels in triplicate culture wells. * indicates a 
signifi  cant difference (P < 0.05) from sham counterpart.JEM VOL. 204, February 19, 2007  327
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production by T cells and that the absence of this receptor 
was associated with lowered IL-17 production by male 
PPARα−/− MOG-reactive splenocytes suggest that NF-κB 
and c-jun transcription factors do not mediate the production 
of this cytokine downstream of antigen signals. These results 
thus align with emerging data that Th17 cells develop via a 
lineage that is separate from Th1 cells (41–44).
It is reported that PPARα must bind either endogenous or 
synthetic lipid ligands to repress NF-κB and c-jun activity (27). 
Our observation that PPARα expression in male T cells was 
associated with lowered DNA binding of these transcrip-
tion factors indicates that PPARα may bind endogenous 
  ligands to eff  ect changes in T cell activation. The identity of 
these natural ligands is not known but may include monoun-
saturated and polyunsaturated fatty acids (C18-C22), the 
lipid mediator oleoylethanolamide, or various eicosanoids 
(5S-  hydroxy-6,8,11,14-eicosatetraenoic acid, or leukotriene 
B4) that are generated during infl  ammatory responses (45–47). 
In addition to these eff   ects of ligand-bound PPARα on 
NF-κB and c-jun, it has also been reported that ligand-free 
PPARα may inhibit the phosphorylation of p38 (48), a   kinase 
that also promotes IFN-γ transcription downstream of TCR 
stimulation (49). Future studies should distinguish whether 
PPARα binds endogenous lipids or acts in a ligand-free 
fashion to mediate its suppressive eff  ects on IFN-γ and TNF 
production.
We found that male RAG2−/− mice reconstituted with 
male PPARα−/− T cells developed an earlier onset of EAE as 
compared with mice provided with WT T cells. Similarly, 
male PPARα−/−mice developed more severe paralysis com-
pared with WT counterparts in the acute phase of EAE, but 
not in subsequent relapses of disease. Collectively, these 
  results indicate that the eff  ect of PPARα in dampening CNS 
infl  ammation in male mice is restricted to the early stages of 
EAE development. These fi  ndings therefore align with   recent 
reports that suggest that Th1 cells (the T cell subset   infl  uenced 
by PPARα) are more important in the initiation of EAE, 
whereas Th17 cells are more critical for disease progression 
(4, 5). An alternative explanation for the limited infl  uence of 
PPARα on disease progression is that once EAE is initiated, 
proinfl   ammatory cytokines present in the circulation may 
neutralize any suppressive eff  ects of the testosterone–PPARα 
axis on immune responses. In support of this notion, serum 
testosterone levels drop in the acute phase of EAE (24), and 
PPARα mRNA levels are suppressed in the liver by 
  infl  ammation (50). Nonetheless, our fi  ndings that PPARα 
plays a role in the initiation of EAE and alters the threshold 
of T cell activation, collectively with our observation that 
Gemfi  brozil altered EAE incidence in males but not females, 
strongly support a role for this molecule in regulating gender 
susceptibility to autoimmune disease.
Our fi  nding that the proinfl  ammatory eff  ect of castration 
was severely blunted in purifi  ed PPARα−/− T cells suggests 
that changes in the expression of PPARα in T cells explain 
the bulk of the eff  ects of androgens on Th fate. However, 
our results do not preclude that sex hormones or chromo-
somes infl   uence the development of Th autoimmunity 
via their action on other genes in T cells or other immune 
cell populations. Indeed, APCs also exhibit gender dimor-
phism in cytokine production (51). Female APCs secrete 
more of the Th1-promoting cytokine IL-12, whereas male 
APCs secrete more IL-10 upon T cell–mediated activation 
(51). A recent study also suggests that male T regulatory cells 
may be more competent at suppressing the activation of 
  autoreactive CD4+ T cells (52). Moreover, our results do not 
take into account the infl  uences of the adipokine leptin (53) 
or the Y chromosome (54) on Th fate. Leptin is present 
in the circulation at higher levels in females and has been 
shown to enhance the Th1 diff  erentiation of myelin-reactive 
cells during EAE (53), whereas Y chromosome–encoded 
genes appear to antagonize the suppressive actions of andro-
gens on Th1 responses (54). Finally, the fact that female 
SV.129 mice (this study) and female mice of other H2b- or 
H2u-restricted strains (17, 18) fail to develop more severe 
EAE, despite having more robust T cell–mediated autoim-
munity than male counterparts (this study and reference 22), 
highlights the role of T cell–independent factors in the devel-
opment of CNS infl  ammation.
In conclusion, our fi   ndings suggest that males tend to 
  develop protective Th2 immune responses because they have 
higher levels of androgens that drive T cell expression of 
PPARα. Our results may help to explain why females are more 
susceptible to develop MS and other autoimmune diseases. 
  Future studies should investigate whether PPARα also exhibits 
a sexual dimorphic pattern of expression in humans and infl  u-
ences the development of MS. This knowledge that androgens 
act through PPARα to dampen infl  ammation should also be 
considered in the design of future clinical trials testing the 
  effi   cacy of fi  brate agonists of this receptor and androgens in the 
treatment of T cell–mediated autoimmune diseases.
MATERIALS AND METHODS
Mice. SV.129 WT (129S1/SvImJ), PPARα−/− (129S4/SvJae-Pparatm1Gonz), 
SJL/J, and C57/BL6 mice were from The Jackson Laboratory. RAG2−/− 
mice (129S6/SvEvTac-Rag2tim1Fwa) were from Taconic Farms. Colonies of 
WT and PPARα−/− mice were maintained in our animal facility. Genotyp-
ing of mice was performed by amplifying a portion of exon 8 of the ligand-
binding domain of PPARα from tail DNA (isolated using a Dneasy kit; 
QIAGEN). Cycling conditions were as follows: 1 min at 94°C, 1 min at 
60°C, and 1 min at 72°C. Primer sequences were: PPARα (sense): 5′-C  A  G-
A  A  G  T  T  G  C  A  G  G  A  G  G  G  G  A  T  T  G  T  G  -3′ and PPARα (antisense): 5′-C  A  G  A-
A  G  T  T  G  C  A  G  G  A  G  G  G  G  A  T  T  G  T  G  -3′.
Adoptive transfer. CD4+ T cells were purifi  ed from the spleens of male 
and female SV.129 WT or PPARα−/− mice using negative selection 
  columns (R&D Systems), and cells were suspended in sterile PBS. 7 × 106 
T cells were injected intravenously into naive male and female RAG2−/− 
recipients 48 h before EAE induction.
EAE induction. EAE was induced in mice (8–12 wk of age) via subcutane-
ous immunization with 100 μg MOG p35-55 in an emulsion (vol ratio of 1:1) 
with CFA (containing 4 mg/ml of heat-killed Mycobacterium tuberculosis 
H37Ra; Difco Laboratories). Mice were also injected intravenously with 
  Bordetella pertussis toxin (Difco Laboratories) in PBS at the time of and 2 d after 
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Facility and purifi  ed by HPLC. Mice (n = 7–10 per treatment group) were 
examined daily for clinical signs of EAE and were scored as followed: 0, no 
clinical disease; 1, limp tail; 2, hindlimb weakness; 3, complete hindlimb paral-
ysis; 4, hindlimb paralysis plus some forelimb paralysis; 5, moribund or dead. 
All animal protocols were approved by the Division of Comparative Medicine 
at Stanford University, and animals were maintained in accordance with the 
guidelines of the National Institutes of Health. Splenocytes were harvested 
from representative mice (n = 2–3/group) at 10 d after immunization.
Histopathology. Brains and spinal cords were dissected from mice, fi  xed in 
10% formalin in PBS, and embedded in paraffi   n. 10-μm-thick sections were 
stained with hematoxylin and eosin. Infl  ammatory lesions in selected brain, 
thoracic, and lumbar spinal cord sections were counted by an examiner 
blinded to the clinical and treatment status of the animal.
Castration and hormone pellet implantation. All surgeries were approved 
by the Division of Comparative Medicine at Stanford University. Mice were 
anaesthetized intraperitoneally with 80 mg/kg ketamine hydrochloride/16 
mg/kg xylazine. For castration surgery, the skin on the   abdomen of each mouse 
was shaved and disinfected, and a mid-ventral incision (1–1.5 cm) was made 
just above the penis to expose the abdominal fat pads. Left and right fat pads 
were each pulled outwards to expose underlying testes. Testes were removed 
by severing each vas deferens using a Bovie cautery stick, and the abdominal 
incision was closed using surgical silk and staples. For sham surgeries, the 
  abdominal fat pads were pulled outwards, but the vas deferens was not severed.
90-d release pellets of 5α-DHT (5 mg dose) or placebo pellets that contained 
carrier binder alone (cholesterol-methyl cellulose-a-lactulose) were purchased 
from Innovative Research of America. To implant pellets, a midline incision was 
made in the scapular area of the neck. Hormone or placebo pellets were  implanted 
subcutaneously, and the incision was closed with surgical staples.
Serum testosterone measurement. Testosterone was measured in the 
serum (from blood drawn at 10 a.m.) by the Department of Comparative 
Medicine at Stanford University.
Activation assays and cytokine analysis. Male or female splenocytes (0.5 × 
106 cells/well) or CD3+ or CD4+ T cells (5 × 104 cells/well) purifi  ed by 
negative selection (columns from R&D Systems) were cultured in fl  at-
  bottomed 96-well plates in media (RPMI 1640 supplemented with 2 mM 
l-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 100 
U/ml penicillin, 0.1 mg/ml streptomycin, 0.5 μM 2-mercaptoethanol, and 
10% FCS) with 1–25 μg/ml MOG p35-55 peptide or with 0.1–5 μg/ml 
each of anti-CD3 (clone 145-2C11; BD Biosciences) and anti-CD28 (clone 
37.51; BD Biosciences).
To assess proliferation rate, cultures were pulsed with [3H]thymidine 
(1 μCi/well) after 24–72 h of culture and 18 h later were harvested onto fi  lter 
paper. The counts per minute of incorporated [3H] thymidine were read 
  using a β counter. Cytokines were measured in the supernatants of cultured 
cells using anti–mouse OPTEIA ELISA kits (BD Biosciences). Supernatants 
were taken at the time of peak production for each cytokine (48 h, IL-2; 72 h, 
IFN-γ, TNF, and IL-17; 120 h, IL-4 and IL-10).
FACS analysis of leukocyte subsets. Spleens were isolated from male 
and female naive SV.129 WT and PPARα−/− mice (n = 3/group). A single 
cell suspension was prepared, and red blood cells were lysed using hypotonic 
buff  er. 106 splenocytes were washed in 1× PBS, centrifuged at 1,200 rpm, 
and incubated with various antibodies from BD Biosciences (1:100 dilution 
in 2% FCS in PBS) in the dark for 20 min at room temperature. Cells were 
then washed three times with 2% FCS in PBS. Propidium iodide was used 
to stain dead cells. Three-color fl  uorescence-activating cell sorting was per-
formed using a FACScan (BD Biosciences). Data were analyzed using FloJo 
software (version 6.3.3).
Real-time RT-PCR. CD4+ and CD3+ T cells were purifi  ed by negative 
selection (columns from R&D Systems). Total RNA was isolated from these 
T cells using the Absolutely RNA RT-PCR Miniprep kit (Statagene). 2 μg 
RNA was reverse-transcribed, and PPARα, PPARδ, PPARγ, and β-actin 
cDNAs were amplifi  ed according to methods described previously (55) us-
ing a Lightcycler (Roche). Primer sequences are as follows: PPARα (same as 
used for genotyping); PPARδ (sense): G  C  C  T  C  G  G  G  C  T  T  C  A  C  T  A  C  ; 
PPARδ (antisense): A  G  A  T  C  C  G  A  T  C  G  C  A  C  T  T  C  T  C  A  ; PPARγ (sense): 
C  C  A  G  A  G  T  C  T  G  C  T  G  A  T  C  T  G  C  G  -3′; PPARγ (antisense): G  C  C  A  C  C  T  C-
T  T  T  G  C  T  C  T  G  A  T  C  -3′; β-actin (sense): 5′-T  G  T  C  C  C  T  G  T  A  T  G  C  C  T  C  T-
G  G  T  -3′; and β-actin (antisense): 5′-C  A  C  G  C  A  C  G  A  T  T  T  C  C  C  T  C  T  C  -3′. 
Amplifi  cation conditions for PPARδ, PPARγ, and β-actin were 94°C for 
5 min, followed by various cycles of 20 s at 94°C, 30 s at 55°C, and 30 s at 72°C.
Western blot analysis. 250 μg of nuclear extract was suspended in 2 vol of 
2× SDS Sample Buff  er (Bio-Rad Laboratories) and subjected to SDS-PAGE 
electrophoresis using 10% Tris-HCl Ready Gels (Bio-Rad Laboratories). 
  Proteins were transferred to PVDF membranes, and immunoblotting was per-
formed using conventional methods (Santa Cruz Biotechnology, Inc.) using a 
rabbit polyclonal PPARα antibody (catalog no. 101710; Cayman Chemical).
DNA binding assays. Spleens from fi  ve to six mice were pooled, and CD3+ 
cells were purifi  ed using negative selection columns (R&D Systems). T cells 
were suspended in media and cultured in fl  at-bottomed six-well plates pre-
coated with 5 μg/ml anti-CD3 and anti-CD28. After 16 h, T cells were har-
vested and nuclear extracts were prepared from these cells using the BD 
Transfactor Extraction kit (BD Clontech) according to the manufacturer’s 
  directions. The concentration of protein in each sample was determined using 
a BCA assay kit (Pierce Chemical Co.). DNA binding assays for NF-κB 
and c-jun were performed using BD Transfactor kits (BD Clontech).
Statistical analysis. Data are presented as means + SEM. When data were 
parametric (kurtosis and skewness <2) and group variances were homoge-
nous (Bartlett homogeneity test), a one-way analysis of variance and Scheff  é 
post-hoc test (for more than two groups) or a t test (n = 2 groups) were used 
to detect between-group diff  erences. When data were nonparametric, ranks 
were compared among groups using a Kruskal-Wallis test and nonparametric 
test for multiple comparisons (for more than two groups) or a Mann-Whitney 
U test (n = 2 groups). A value of P < 0.05 was considered signifi  cant.
Online supplemental material. Fig. S1 shows real-time PCR analysis of 
PPARα, PPARγ, and PPARδ mRNA expression in mouse CD4+ cells. 
A and B show that the expression of PPARα is higher in WT male versus 
female CD4+ cells derived from C57BL/6 and SJL/J strains. C shows that 
PPARα expression is altered in CD4+ cells at 48 h after stimulation with 
5 μg/ml anti-CD3 and 5 μg/ml anti-CD28. D shows that PPARδ and 
PPARγ mRNAs are up-regulated in a compensatory fashion in CD4+ 
cells in the absence of PPARα. Fig. S1 is available at http://www.jem
.org/cgi/content/full/jem.20062839/DC1.
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